146.92
146.92 (0%)
As of Feb 14, 2025
Repligen Corp [RGEN]
Source:
Company Overview
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs.
| Country | United States |
| Headquarters | waltham |
| Phone Number | 7814499560 |
| Industry | manufacturing |
| CEO | Oliver Loeillot |
| Website | www.repligen.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $634.4 |
| Operating Profit | $-35.1 |
| Net Income | $-25.5 |
| Net Cash | $6 |
Profit Ratios
| Gross Margin | $274.6 |
| Operating Margin | -5.5 |
| Profit as % of Revenues | -1,076.5% |
| Profit as % of Assets | -0.9% |
| Profit as % of Stockholder Equity | -1.3% |
Management Effectiveness
| Return on Equity | -1.3% |
| Return on Assets | -0.9% |
| Turnover Ratio | 22.4% |
| EBITA | $-35.1 |
Balance Sheet and Cash Flow Measures
| Total Assets | $2,829.7 |
| Total Liabilities | $856.9 |
| Operating Cash Flow | $175.4 |
| Investing Cash Flow | $-86.4 |
| Financing Cash Flow | $-82.9 |
